EV-309: An Open-Label, Randomized, Phase 3 Study of Enfortumab Vedotin + Pembrolizumab for Bladder Preservation in Patients with #MIBC. Presented by @MattGalsky @TischCancer. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/47APfwo @myESMO
453 views · 4 likes · 6 reposts · 1 reply
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgHealth-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEY
https://esmocongress.esmo.orgEnfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.orgEnfortumab Vedotin Plus Pembrolizumab (EV+P) For Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Updated Exploratory Analysis of EV-302 in Older Patients (pts) and Those With Comorbidities
https://esmocongress.esmo.org- Wenchang Yue@WenchangYue
@urotoday @MattGalsky @TischCancer @zklaassen_md @myESMO Good to have a written recap of the bladder preservation session.
Source: UroToday.com · x.com